Biohaven
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develo...
Latest News
18 days ago · prnewswire.com
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial ResultsThe US Food and Drug Administration (FDA) accepted new drug application resubmission for Vyglxia (troriluzole) in spinocerebeller ataxia (SCA), user fee goal date 1Q27. Announced exclusive global license with SK Biopharmaceuticals Co., Ltd.
26 days ago · barrons.com
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug AgainThe Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven's experimental spinocerebellar ataxia treatment.
26 days ago · benzinga.com
Biohaven Rebounds With FDA Review Date for Rare Disease DrugBiohaven Ltd. (NYSE:BHVN) stock is surging on Thursday with a session volume of 10.293 million versus an average volume of 2.585 million after an update on the spinocerebellar ataxia (SCA) program.
1 month ago · benzinga.com
Biohaven Expands Asian Licensing Footprint Through Strategic Ono AgreementBiohaven Ltd. (NYSE:BHVN) entered into a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.
1 month ago · gurufocus.com
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' DiseaseBiohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phas
2 months ago · gurufocus.com
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORT
2 months ago · prnewswire.com
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials NEW YORK, Sept. 11, 2026 /PRNewswire/ -- Biohaven Ltd (NYSE: BHVN) dropped $2.21, or about 14.73%, on September 10, 2026 after the Company disclosed that the FDA placed a partial clinical hold on new-patient enrollment in the Company's BHV-7000/opakalim epilepsy trials.
2 months ago · barrons.com
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
2 months ago · benzinga.com
FDA Pauses New Enrollment for Biohaven Epilepsy Drug ProgramBiohaven Ltd. (NYSE:BHVN) on Thursday announced a partial clinical hold issued by the U.S. Food and Drug Administration (FDA) on new patient enrollment for its BHV-7000 program, while maintaining timelines for its lead pivotal study in refractory focal epilepsy.
2 months ago · reuters.com
US FDA pauses new enrollment in Biohaven's epilepsy drug trialsBiohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug after rodent findings, sending its shares down more than 13% in premarket trading.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BHVN